Rivanna Medical said today it commercially launched its Accuro anesthesia guidance device in the U.S., and said it is in continuing discussions with 3 potential corporate partners.
The announcement was made at the American Society of Anesthesiologists annual meeting in San Diego last week.
The Accuro system provides 3D navigation for needle insertions to improve clinician accuracy in placement, the Charlottesville, Va.-based Rivanna Medical said.
“Anesthesia providers attending the recent ASA scientific meeting told us that Accuro fulfills a significant unmet clinical need for automated image guidance, especially in the spinal anesthesia sector. Knowing the variable configuration of an individual’s lumbar anatomy for a specific patient is essential to predicting the appropriate puncture site, needle trajectory, and depth of needle insertion to reach the epidural space. But without medical imaging, the physician is left to guesswork.” CEO John Williams said in a press release.
Data from a clinical study of the device reported a 94% rate of success in identifying epidural space through its 3D image automation technology, Rivanna Medical said.
In July, Rivanna said it won FDA 510(k) clearance for its Accuro handheld needle guidance device indicated for spinal anesthesia.
Blind needle guidance can lead to failed spinal anesthesia, Rivanna said. Of the over 20 million epidural and spinal anesthesia procedures per year, over 20% fail, the company said.
In June, Rivanna Medical said it named Dr. Brendan Carvalho of the Stanford University Medical Center to its clinical advisory board.